Tramazoline + Dexamethasone


Generic Medicine Info
Indications and Dosage
Nasal
Allergic rhinitis
Adult: Each metered dose contains tramazoline HCI 120 mcg and dexamethasone isonicotinate 20 mcg: 1 metered dose into each nostril bid/tid, titrated to the lowest effective dose. Up to 6 times in 24 hr. Max treatment duration: 14 days.
Child: Each metered dose contains tramazoline HCI 120 mcg and dexamethasone isonicotinate 20 mcg: <5 yr: Not recommended. 5-12 yr: 1 metered dose into each nostril up to bid. Max treatment duration: 14 days.
Elderly: Each metered dose contains tramazoline HCI 120 mcg and dexamethasone isonicotinate 20 mcg: 1 metered dose into each nostril bid/tid, titrated to the lowest effective dose. Up to 6 times in 24 hr. Max treatment duration: 14 days.
Contraindications
Infants. Lactation.
Special Precautions
Pregnancy. Not for prolonged use. Monitor height of children on prolonged treatment. Consider additional systemic corticosteroid cover during periods of stress or elective surgery if treated with doses higher than recommended.
Adverse Reactions
Burning sensation in nose, sneezing. Rebound congestion after prolonged use.
Overdosage
Symptoms: Pallor, sweating, tachycardia, anxiety. Management: Treatment is symptomatic.
Action
Description: Tramazoline is a sympathomimetic with actions similar to naphazoline. It produces a fast and long lasting decongestant effect on the nasal mucosa. Dexamethasone is a corticosteroid with anti-inflammatory and anti-allergic properties.
Pharmacokinetics:
Absorption: Dexamethasone: Readily absorbed from GI tract.
Distribution: Dexamethasone: Protein binding: 77%. Crosses placenta.
Excretion: Dexamethasone: Excreted in urine (65%).
Storage
Store below 25°C. Discard 6 mth after opening.
MIMS Class
Nasal Decongestants & Other Nasal Preparations
Disclaimer: This information is independently developed by MIMS based on Tramazoline + Dexamethasone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in